Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy
Purpose The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The role of consolidative radiation therapy (RT) in the setting of R-CHOP chemotherapy is not well reported. This retros...
Saved in:
| Main Author: | |
|---|---|
| Format: | article |
| Published: |
2010
|
| Online Access: | http://hdl.handle.net/10725/2256 http://dx.doi.org/10.1200/JCO.2009.27.3441 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513457847533568 |
|---|---|
| author | Zreik, Tony |
| author_facet | Zreik, Tony |
| author_role | author |
| dc.creator.none.fl_str_mv | Zreik, Tony |
| dc.date.none.fl_str_mv | 2010 2015-10-06T08:45:51Z 2015-10-06T08:45:51Z 2015-10-06 |
| dc.identifier.none.fl_str_mv | 0732-183X http://hdl.handle.net/10725/2256 http://dx.doi.org/10.1200/JCO.2009.27.3441 Phan, J., Mazloom, A., Medeiros, L. J., Zreik, T. G., Wogan, C., Shihadeh, F., ... & Dabaja, B. S. (2010). Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. Journal of Clinical Oncology, 28(27), 4170-4176. |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | Journal of Clinical Oncology |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Purpose The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The role of consolidative radiation therapy (RT) in the setting of R-CHOP chemotherapy is not well reported. This retrospective analysis is an attempt to clarify this role. Patients and Methods Subjects were 469 patients with histologically confirmed DLBCL treated between January 2001 and December 2007. Variables including age, sex, Ann Arbor disease stage, bulky disease status, standardized uptake values (SUVs) on positron emission tomography (PET), International Prognostic Index (IPI), and Ki67 staining (proliferation). Results Of 469 patients, 190 (40.5%) had stage I or II disease and 279 (59.5%) had stage III or IV disease, 327 (70%) had at least six cycles of R-CHOP, and 142 (30.2%) had involved-field RT (dose, 30 to 39.6 Gy) after complete response to chemotherapy. Median follow-up was 36 months (range, 8 to 85 months). Multivariate analysis showed that RT (P < .0001), IPI score (P = .001), response to therapy (P = .001), use of six to eight cycles of R-CHOP (P < .001), and combined presence (P = .006) or absence (P = .025) of high Ki67, high PET SUV, and bulky disease influenced overall survival (OS) and progression-free survival (PFS). Matched-pair analyses of patients who received six to eight cycles of R-CHOP with stage I or II disease (44 pairs) and all stages (74 pairs) indicated that RT improved OS (hazard ratio [HR], 0.52 and 0.29, respectively) and PFS (HR, 0.45 and 0.24, respectively) compared with no RT. Conclusion This study showed significant improvements in OS and PFS among patients who received consolidation RT after R-CHOP chemotherapy for DLBCL. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_d8a952f45293930c77b8d60ba6d4da54 |
| identifier_str_mv | 0732-183X Phan, J., Mazloom, A., Medeiros, L. J., Zreik, T. G., Wogan, C., Shihadeh, F., ... & Dabaja, B. S. (2010). Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. Journal of Clinical Oncology, 28(27), 4170-4176. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/2256 |
| publishDate | 2010 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapyZreik, TonyPurpose The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The role of consolidative radiation therapy (RT) in the setting of R-CHOP chemotherapy is not well reported. This retrospective analysis is an attempt to clarify this role. Patients and Methods Subjects were 469 patients with histologically confirmed DLBCL treated between January 2001 and December 2007. Variables including age, sex, Ann Arbor disease stage, bulky disease status, standardized uptake values (SUVs) on positron emission tomography (PET), International Prognostic Index (IPI), and Ki67 staining (proliferation). Results Of 469 patients, 190 (40.5%) had stage I or II disease and 279 (59.5%) had stage III or IV disease, 327 (70%) had at least six cycles of R-CHOP, and 142 (30.2%) had involved-field RT (dose, 30 to 39.6 Gy) after complete response to chemotherapy. Median follow-up was 36 months (range, 8 to 85 months). Multivariate analysis showed that RT (P < .0001), IPI score (P = .001), response to therapy (P = .001), use of six to eight cycles of R-CHOP (P < .001), and combined presence (P = .006) or absence (P = .025) of high Ki67, high PET SUV, and bulky disease influenced overall survival (OS) and progression-free survival (PFS). Matched-pair analyses of patients who received six to eight cycles of R-CHOP with stage I or II disease (44 pairs) and all stages (74 pairs) indicated that RT improved OS (hazard ratio [HR], 0.52 and 0.29, respectively) and PFS (HR, 0.45 and 0.24, respectively) compared with no RT. Conclusion This study showed significant improvements in OS and PFS among patients who received consolidation RT after R-CHOP chemotherapy for DLBCL.PublishedN/A2015-10-06T08:45:51Z2015-10-06T08:45:51Z20102015-10-06Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article0732-183Xhttp://hdl.handle.net/10725/2256http://dx.doi.org/10.1200/JCO.2009.27.3441Phan, J., Mazloom, A., Medeiros, L. J., Zreik, T. G., Wogan, C., Shihadeh, F., ... & Dabaja, B. S. (2010). Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. Journal of Clinical Oncology, 28(27), 4170-4176.enJournal of Clinical Oncologyinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/22562016-08-25T08:58:25Z |
| spellingShingle | Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy Zreik, Tony |
| status_str | publishedVersion |
| title | Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy |
| title_full | Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy |
| title_fullStr | Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy |
| title_full_unstemmed | Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy |
| title_short | Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy |
| title_sort | Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy |
| url | http://hdl.handle.net/10725/2256 http://dx.doi.org/10.1200/JCO.2009.27.3441 |